Intravitreal Bevacizumab versus Laser Therapy in Retinopathy of Prematurity: Analyzing Retreatment Rates, Timing, and Risk Predictors
Posted innews Ophthalmology Pediatrics

Intravitreal Bevacizumab versus Laser Therapy in Retinopathy of Prematurity: Analyzing Retreatment Rates, Timing, and Risk Predictors

This study compares retreatment rates and timing in retinopathy of prematurity among infants treated with intravitreal bevacizumab versus laser therapy, highlighting lower early retreatment rates and delayed intervention in the bevacizumab group, especially in high-risk premature infants.
Challenges in Using Insulin Dose-Adjusted HbA1c to Identify Partial Remission in Pediatric Type 1 Diabetes: Insights from the SEARCH for Diabetes in Youth Study
Posted inDiabetes & Endocrinology news Pediatrics

Challenges in Using Insulin Dose-Adjusted HbA1c to Identify Partial Remission in Pediatric Type 1 Diabetes: Insights from the SEARCH for Diabetes in Youth Study

This study highlights the limitations of insulin dose-adjusted hemoglobin A1c (IDAA1c) ≤9 in detecting partial remission in US youth with type 1 diabetes, especially those with overweight or obesity, suggesting BMI-specific adjustments improve accuracy but reduce specificity.
Immunogenicity up to Age 5 Following Single- or Two-Dose Infant Primary Series of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine with Booster in South Africa: Extended RCT Follow-Up
Posted inClinical Updates news Pediatrics Public Health

Immunogenicity up to Age 5 Following Single- or Two-Dose Infant Primary Series of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine with Booster in South Africa: Extended RCT Follow-Up

This review synthesizes long-term immunogenicity data from a South African RCT comparing 1+1 and 2+1 infant PCV10 and PCV13 schedules. PCV13 1+1 schedules maintain durable immunity up to age 5, supporting schedule optimization in established programs.